摘要
目的探讨帕罗西汀联合脑生物反馈仪治疗混合性焦虑和抑郁障碍的临床效果与安全性。方法采用前瞻性研究方法,选取2014年8月至2017年9月遂宁市民康医院收治的混合性焦虑和抑郁障碍患者120例,以简单化随机分组方法将患者分为观察组(n=60)与对照组(n=60),两组患者均给予帕罗西汀治疗,起始剂量为20 mg/d,每周酌情增加10 mg/d,最终剂量为20~60 mg/d。观察组加用脑生物反馈仪治疗,每周训练2次,每次训练持续20 min。两组患者均连续治疗6周为1个疗程,比较两组患者入组时以及治疗开始后2周、4周、6周的汉密尔顿抑郁量表(HAMA)与汉密尔顿焦虑量表(HAMD)评分,比较两组治疗中的不良反应发生情况。结果治疗前两组患者的HAMA评分差异无统计学意义(P>0.05),治疗后2、4、6周患者的HAMA评分均明显下降(P<0.05),同一时间观察组HAMA评分均明显低于对照组(P<0.05);治疗前两组患者的HAMA评分差异无统计学意义(P>0.05),治疗后2、4、6周患者的HAM评分均明显下降(P<0.05),同一时间观察组HAMA评分均明显低于对照组(P<0.05);两组患者治疗过程中均没有出现严重不良反应,观察组患者不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论帕罗西汀联合脑生物反馈仪治疗对混合性焦虑和抑郁障碍患者的疗效更为明显,患者焦虑与抑郁不良情绪明显改善,安全性也较高。
Objective To explore the clinical efficacy and safety of paroxetine combined with cerebral biofeedback instrument in treatment of patients with mixed anxiety and depressive disorder. Methods This is a prospective study,a total of 120 patients with mixed anxiety and depression disorder during August 2014 to September 2017 in this hospital were divided into observation group（ n = 60） and control group（ n = 60）according to simple random grouping method,patients in these two groups were given with paroxetine for treatment,the initial dosage was 20 mg/d,increased 10 mg/day per week as appropriate dosage,the final dosage was 20 ~ 60 mg/d. Patients in observation group were additionally treated with cerebral biofeedback device 2 times a week,and each time lasted for 20 min. Patients in these two groups were treated for 6 weeks as 1 course. Hamilton Depression Scale（ HAMA） and Hamilton Anxiety Scale（ HAMD） scores of these two groups were compared at the beginning of treatment,2 weeks,4 weeks and 6 weeks after the treatment. Results The difference in HAMA scores between these two groups was not significant（ P〈0. 05）,the difference in HAMA scores before treatment,after treatment for 2,4 and 6 weeks in patients was significantly decreased（ P〈0. 05）. At the same time,HAMA scores in observation group were significantly lower than those of control group（ P〈0. 05）. The HAMA scores between these two groups had no significant difference before treatment（ P〈0. 05）. HAMA scores in patients after treatment for 2,4 and6 weeks were significantly decreased（ P〈0. 05）,at the same time,HAMA scores in observation group were significantly lower than those of patients in control group（ P〈0. 05）. There was no serious adverse reactions in patients of these 2 groups,and the difference in incidence of adverse reactions in observation group compared with that of control group was not statistically significanct（ P〈0. 05）. Conclusion Paroxetine combined with cerebral biofeedback therapy are
作者
廖英
范红
肖烈
全秀君
秦龙
刘珊珊
魏娜
LIAO Ying;FAN Hong;XIAO Lie;et al(Suining citizen kang hospital psychiatric department, Suining Sichuan 629000, China)
出处
《临床和实验医学杂志》
2018年第9期967-970,共4页
Journal of Clinical and Experimental Medicine
基金
四川省科技支撑计划项目(编号:S20160012)
